ABCA2 GIRMS Analytical Validation Clinical Performance Study

Status Completed

Clinical Trial Summary

The purpose of this study is to collect human breath samples for use in a validation study intended to demonstrate equivalent clinical performance measures of new ABCA2 GIRMS (Automated Breath Carbon Analyzer-2 Gas Isotope Ratio Mass Spectrometer) instruments to the currently FDA-approved ABCA GIRMS (Automated Breath Carbon Analyzer Gas Isotope Ratio Mass Spectrometer) system. ABCA GIRMS systems are used to analyze the ratio of 13CO2 to 12CO2 in patient breath samples during the GEBT (Gastric Emptying Breath Test) procedure.

Clinical Trial Description

In this study the participants will be administered the FDA-approved GEBT test, which involves collecting breath samples prior to and after consumption of a non-radioactive carbon stable isotope (13C) labeled test meal. Breath samples will be collected at times consistent with FDA approved labeling. Participant's breath samples will be analyzed on the currently approved ABCA GIRMS and on the new ABCA2 GIRMS instruments. The values collected from both systems will be used to determine the clinical diagnostic agreement at each individual time points and percent agreement in diagnosis between the approved ABCA GIRMS and the new ABCA2 GIRMS. ;

Study Design

Related Conditions & MeSH terms

Gastroparesis

Clinical Trial Details

NCT number	NCT04607304
Study type	Interventional
Source	Cairn Diagnostics
Contact
Status	Completed
Phase	N/A
Start date	October 8, 2020
Completion date	July 27, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03941288` - Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia	Phase 2
Terminated	`NCT03285308` - A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01	Phase 3
Completed	`NCT00733551` - Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects.	Phase 1
Completed	`NCT01650714` - Endoscopic Full Thickness Biopsy, Gastric Wall.	N/A
Completed	`NCT01452815` - Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis	Phase 2
Completed	`NCT01039974` - GSK962040 Drug-drug Interaction Study With Ketoconazole	Phase 1
Terminated	`NCT04844190` - Use of EndoFLIP and Manometry Prior to G-POEM	N/A
Enrolling by invitation	`NCT06215547` - Medtronic Enterra II Neurostimulator	N/A
Completed	`NCT04026997` - A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis	Phase 2
Completed	`NCT00562848` - A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040	Phase 1
Enrolling by invitation	`NCT04207996` - Vagus Nerve Response in Gastroparesis Patients
Recruiting	`NCT06068114` - Gastric Pathophysiology in Diabetes
Completed	`NCT03259841` - Ultrasound Assessment of Gastric Contents in Fasted Patient Undergoing Cholecystectomy
Active, not recruiting	`NCT04300127` - Pioglitazone for Idiopathic Gastroparesis	Early Phase 1
Recruiting	`NCT01696734` - Domperidone in Treating Patients With Gastrointestinal Disorders	Phase 3
Terminated	`NCT04635306` - 13C-Spirulina Nitrogen Content GEBT Study	N/A
Withdrawn	`NCT02420925` - Effect of Celiac Plexus Block on Gastric Emptying and Symptoms Caused by Gastroparesis	N/A
Recruiting	`NCT00777439` - Domperidone for Refractory Gastrointestinal Disorders	N/A
Terminated	`NCT00760461` - Domperidone in Refractory Gastroparesis	Phase 2
Completed	`NCT00612014` - Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis	Phase 2